Pharmacological management of osteoporosis in nursing home residents: the Shelter study.
Study Goal
The researchers aimed to assess the prevalence of pharmacological osteoporosis prevention (including vitamin D, calcium, and bisphosphonates) in nursing home residents and its association with patient characteristics such as falls, fractures, cognitive impairment, and dependence in walking.
Results Summary
The study found low usage of osteoporosis medications (OMs) among nursing home residents, with only 1.5% using all three classes (vitamin D, calcium, and bisphosphonates). Usage varied widely by country, and under-treatment was noted in residents with recent falls, fractures, or walking dependence, while possible over-treatment occurred in those with high mortality risk.
Population
Nursing home residents from eight countries (Czech Republic, England, Finland, France, Germany, Italy, The Netherlands, and Israel).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D | no change | osteoporosis prevention | nursing home residents | 16.2% | used by | #1 |
calcium | no change | osteoporosis prevention | nursing home residents | 10.4% | used by | #2 |
bisphosphonates | no change | osteoporosis prevention | nursing home residents | 4.5% | used by | #3 |
vitamin D, calcium and bisphosphonates | no change | osteoporosis prevention | nursing home residents | 1.5% | used by | #4 |
bisphosphonate | no change | osteoporosis prevention | residents with a recent fracture | 9.5% | used by | #5 |
vitamin D, calcium and bisphosphonates | no change | osteoporosis prevention | residents with a recent fracture | 2.7% | used by | #6 |
vitamin D | no change | osteoporosis prevention | patients with recent falls | 20.8% | used by | #7 |
calcium | no change | osteoporosis prevention | patients with recent falls | 15.3% | used by | #8 |
vitamin D | no change | osteoporosis prevention | residents with severe cognitive impairment | 15.5% | used by | #9 |
calcium | no change | osteoporosis prevention | residents with severe cognitive impairment | 9.3% | used by | #10 |
bisphosphonate | no change | osteoporosis prevention | bisphosphonate users | 33.7% | used by | #11 |
calcium | no change | osteoporosis prevention | bisphosphonate users | 25.8% | used by | #12 |
vitamin D | no change | osteoporosis prevention | bisphosphonate users | 17.4% | used by | #13 |
any osteoporosis medication | no change | use | nursing home residents across countries | from 66.8% in Finland to 3.0% in Israel | varied widely | #14 |
pharmacological prevention | decrease | osteoporosis prevention | residents with recent falls, fractures and dependence in walking | - | substantial under-treatment | #15 |
bisphosphonate | decrease | vitamin D-calcium combination use | bisphosphonate users | - | only two-thirds also took | #16 |
preventive pharmacotherapy | increase | osteoporosis prevention | residents with high mortality risk | - | possible over-treatment | #17 |
pharmacological prevention | no change | osteoporosis prevention | residents between countries | - | differed substantially | #18 |
OBJECTIVE: To prevent osteoporotic fractures in nursing home residents a combination of bisphosphonates, calcium and vitamin D is recommended. This study assessed the prevalence of pharmacological osteoporosis prevention in nursing home residents from eight countries, and assessed its association with patient characteristics. DESIGN: Cross-sectional analyses of the SHELTER study data. We assessed the overall prevalence of osteoporosis medication (OM) use (vitamin D, calcium and bisphosphonates) in residents stratified for falls and fractures over last 30 days, health instability with high mortality risk, cognitive impairment, and dependence in walking. SETTING AND PARTICIPANTS: Nursing home residents in the Czech Republic, England, Finland, France, Germany, Italy, The Netherlands and Israel. RESULTS: Of 3832 eligible residents, vitamin D, calcium and bisphosphonates were used by 16.2%, 10.4%, and 4.5% respectively. All 3 classes of OM together were used by 1.5% of all residents. Of residents with a recent fracture, 9.5% used a bisphosphonate (2.7% all 3 OMs). In patients with recent falls, 20.8% used vitamin D and 15.3% calcium. In residents with severe cognitive impairment, 15.5% used vitamin D and 9.3% used calcium. Of the bisphosphonate users, 33.7% also used both vitamin D and calcium, 25.8% used only calcium in addition and 17.4% only vitamin D in addition. The use of any OM varied widely across countries, from 66.8% in Finland to 3.0% in Israel. CONCLUSIONS AND IMPLICATIONS: We found substantial pharmacological under-treatment of prevention of osteoporosis in residents with recent falls, fractures and dependence in walking. Only two-thirds of bisphosphonate users also took a vitamin D-calcium combination, despite guideline recommendations. On the other hand, possible over-treatment was found in residents with high mortality risk in whom preventive pharmacotherapy might not have still been appropriate. The prevalence of pharmacological prevention of osteoporosis differed substantially between countries. Efforts are needed to improve pharmacotherapy in residents.